PfSPZ Vaccine

Proteome-wide analysis of a malaria vaccine study reveals personalized humoral immune profiles in Tanzanian adults

Tags:

plasmodium falciparum sporozoites, PfSPZ Vaccine, malaria vaccine, Tanzania, adults

Author(s):

Camponovo F, Campo JJ, Penny MA, et al.

Reference:

Elife. 2020 Jul 14; 9:e53080

Tanzanian adult male volunteers were immunized by direct venous inoculation with radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum (Pf) sporozoites (PfSPZ Vaccine) and protective efficacy assessed by homologous controlled human malaria infection (CHMI). Serum immunoglobulin G (IgG) responses were analyzed longitudinally using a Pf protein microarray covering 91% of the proteome, providing first insights into naturally acquired and PfSPZ Vaccine-induced whole parasite antibody profiles in malaria pre-exposed Africans.

Caregiver and community perceptions and experiences participating in an infant malaria prevention trial of PfSPZ Vaccine administered by direct venous inoculation: a qualitative study in Siaya County, western Kenya

Tags:

sub-Saharan Africa, malaria, PfSPZ Vaccine, Kenya

Author(s):

Florence Achieng, Joseph G. Rosen, Reuben Yego Cherop, Simon Kariuki, Stephen L. Hoffman, Robert Seder, Martina Oneko and Laura C. Steinhardt

Reference:

Malaria Journal 2020 19:226, 24 June 2020

Despite available control strategies, malaria morbidity and mortality, especially in infants and young children in sub-Saharan Africa, remain intractable. Malaria vaccination could substantially reduce malaria episodes and deaths. One vaccine candidate is the whole sporozoite PfSPZ Vaccine, consisting of irradiated cryopreserved sporozoites administered by direct venous inoculation (DVI). DVI may be less acceptable than more familiar administration routes, particularly intramuscular. As part of a PfSPZ Vaccine trial among infants in western Kenya, a qualitative study was conducted to explore caregiver and community perceptions of the malaria vaccine trial, including the unique DVI administration procedure.

Not Open Access | Increase of dose associated with decrease in protection against controlled human malaria infection by PfSPZ Vaccine in Tanzanian adults

Tags:

Increase of dose, protection, controlled, human malaria infection, PfSPZ Vaccine

Author(s):

Jongo SA, Church LWP, Hoffman SL, et al.

Reference:

Clin Infect Dis. 2019 Nov 29. pii: ciz1152

A vaccine would be an ideal tool for reducing malaria’s impact. PfSPZ Vaccine (radiation attenuated, aseptic, purified, cryopreserved Plasmodium falciparum [Pf] sporozoites [SPZ]) has been well tolerated and safe in >1,526 malaria-naïve and experienced 6-month to 65-year-olds in the U.S., Europe, and Africa. When vaccine efficacy (VE) of 5 doses of 2.7x105 PfSPZ of PfSPZ Vaccine was assessed in adults against controlled human malaria infection (CHMI) in the U.S. and Tanzania and intense field transmission of heterogeneous Pf in Mali, Tanzanians had the lowest VE (20%).

Country:

Tanzania

Search form

You are here